Southwest biologic drug production boom! Huiyu Pharma, Jingze Biology, Weizijin Biology and other local pharmaceutical companies gather in 2026BPD Chengdu.

In recent years, the labels attached to Chengdu have beenNew Drug Innovation Hub— In a series of major international deals, BeiLai Tianheng and Kelun-Biotech have led the way, with cumulative overseas transaction value from Chengdu's new drug projects totaling approximately 260 billion USD over the past three years. In 2026, a wave of projects is now reaching their next critical milestone:Workshops under construction, production lines in progress, certifications and inspections queued.

This shift will raise many new questions and create a wave of confirmed procurement needs.11 5-6, Chengdu is the hub for centralized matchmaking.Bring together decision-makers in Southwest China who are expanding production and selecting suppliers with the vendors ready to meet their needs—all in one place.

1 Capacity Deployment and Emerging Modalities: Concentrated Release of Procurement Demand

Biologics in Southwest China are shifting from R&D to manufacturing.ADC/XDC, Peptide/GLP-1, Nucleic Acid, Radiopharmaceuticals, CGTWait for core track capacity to be concentrated and launched.

ADC/XDCShifted from "can we do it" to "how to do it reliably."Chongqing HaoyuanProduction started: 12 kL antibody bulk and 1500kg kL ADC bulk are active, passed EU QP audit.Henlius、Catalyst BiopharmaAs production capacity and revenue grow in tandem, comparability, DAR control, high-concentration formulations, and conjugation verification become critical once scale is achieved.Capture procurement needs for chromatography, filtration, characterization, validation, and environmental monitoring.

Nucleic Acids & Peptides/GLP-1These are the two fastest-growing lines in Southwest China.Prodrugs、Vesijun BiologyAs production scales up from pilot to commercial scale, process scaling, delivery systems, and analytical methods require re-evaluation to address corresponding needs for synthesis reagents, purification media, and delivery systems.

Radiopharmaceuticals and CGTBuild from scratch according to mass production standards.SPIC Nuclide Innovation (Chongqing)The Phase I investment is approximately 9.18 billion yuan. The project will be completed and accepted in 7 of year 2026, and commence operations in year 2027.Chengdu-side CGT strengthAdvance in parallel. Without an established supply chain, equipment, consumables, and quality control methods must all be built from scratch.

As production scales up, new challenges emerge—clarifying needs in process, compliance, and procurement. 11 5-6, Chengdu: these requirements will be addressed on-site.

2

Once capacity ramps up, the next challenge is efficiency.

As Southwest's capacity shifts from "sufficient" to "cost-conscious," digitalization, automation, and smart factories are no longer optional—they're essential.

Production capacity can be assessed through data, but true collaboration ultimately requires in-person meetings. The workshops, production lines, and certification milestones mentioned above...Behind it are businesses and a group of people making decisions.How to scale the process, control impurities, build the system, and select consumables.

Most of them were in Chengdu from 5 to 6 of 11.

2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityHosted by Eumed, co-organized by Kelun-Biotech. Confirmed innovation partners include Jingze Bio, Haibowei Pharma, Zhishan Weixin, and Wisjinzin Biology. The event will bring together2000+Professional Buyers,70+Keynote Speaker.

In addition to the technical forum, the conference also features specially curatedFull-chain exhibitionandBPD Match Procurement Appointment, and setProcurement in Practice(Daily 15:30),MasterclassandExclusive Lunch Event, creating direct dialogue and efficient matchmaking opportunities for both supply and demand sides.

3 For upstream players, this is a difficult-to-replicate window of opportunity.

Every move in Southwest China translates to a procurement list.: ADC quality control drives chromatography, filtration, and characterization; bioburden release validation and environmental monitoring are verified. Peptide and nucleic acid scale-up necessitates new selection of synthesis reagents, purification resins, and delivery systems. Nuclear medicine and CGT require a complete supply chain re-evaluation...

The challenge is scheduling people. Southwest clients are scattered across Chengdu, Chongqing, Luzhou, and other locations. Booking two or three stops in a single trip is considered successful; more often than not, appointments get rescheduled.

ButIn Chengdu, 2026BPD，Leading companies in Southwest China that are currently building workshops and selecting equipment will attend.Decision makers from process, production, quality, and procurement will share the same venue.

This is why more upstream teams are betting on this Southwest opportunity through a single, concentrated engagement: not just buying two days of ad exposure, but...Connect with key decision-makers in this procurement cycle over two consecutive days.Value extends beyond the event dates — a connection made in person often leads to future opportunities.Long-term relationships and collaboration opportunities.

2026BPD Chengdu booth availability is running low! Book now to secure your spot in the Southwest biopharma expansion window.